title: [Guidelines for drug therapy of postmenopausal osteoporosis].
abstract: Osteoporosis is known as a condition characterized by low bone mass and microarchitectural deterioration of bone tissue leading to bone fragility and a consequent susceptibility to fracture. Osteoporosis has its highest rate of occurrence in postmenopausal women, and in Western countries it has been estimated that for white women aged fifty, the life-time risk of developing an osteoporotic fracture is nearly 40%. Given the consequences of osteoporosis, the most important goal of therapy is to prevent fractures. In Austria, several pharmacologic options for treatment of osteoporosis are available, including bisphosphonates (alendronate, etidronate, risedronate), selective estrogen receptor modulators (raloxifene), calcitonins (salm-calcitonin, elcatonin), fluorides (sodium-fluoride, monofluorophosphate), anabolic steroids (nandrolone-decanoate), steroid derivates (tibolone), estrogen and hormone replacement therapy. An evidence-based evaluation of these treatment options clearly indicates that alendronate, risedronate and raloxifene sufficiently reduce the risk of vertebral fractures. There is less evidence for reduction of vertebral fracture risk for etidronate, calcitonin, estrogen replacement therapy or hormone replacement therapy. Only alendronate and risedronate have been shown to reduce the risk of hip fractures. Calcium and vitamin D are useful adjuncts to any specific treatment for osteoporosis, particularly when Calcium and vitamin D deficiencies have been diagnosed. Also, there is good evidence that in women with Calcium and vitamin D deficiency, a combination of Calcium and vitamin D may reduce the risk of non-vertebral fractures. There is no evidence so far that a combination therapy of antiresorptive drugs would result in reduced fracture risk.
authors.affiliation: Klinischen Abteilung für Endokrinologie und Nuklearmedizin der Medizinischen Universitätsklinik, Auenbruggerplatz 15, A-8036 Graz. hans.dimai@kfunigraz.ac.at
authors.forename: H P
authors.initials: HP
authors.lastname: Dimai
authors.forename: P
authors.initials: P
authors.lastname: Pietschmann
authors.forename: H
authors.initials: H
authors.lastname: Resch
authors.forename: G
authors.initials: G
authors.lastname: Leb
authors.forename: K
authors.initials: K
authors.lastname: Klaushofer
mesh_terms: D000328:Adult; D000368:Aged; D015519:Bone Density / Q000187:drug effects / Q000502:physiology; D003720:Densitometry / Q000379:methods; D019317:Evidence-Based Medicine; D005260:Female; D005598:Fractures, Spontaneous / Q000517:prevention & control*; D006801:Humans; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000175:diagnosis / Q000188:drug therapy*; D017410:Practice Guidelines as Topic; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors